In general, mice treated with ACM‐Trp2 + ACM‐CpG had higher frequencies of CD8+ and CD4+ T cells in the blood, skin drLN, and tumour as compared to mice treated with free Trp2 + free CpG. This evidence concerns the gene CD8A and neoplasm.